| 11C-methionine PET/CT and MRI of primary central nervous system diffuse large B-cell lymphoma before and after high-dose methotrexate SJ Jang, KH Lee, JY Lee, JY Choi, BT Kim, SJ Kim, WS Kim Clinical nuclear medicine 37 (10), e241-e244, 2012 | 26 | 2012 |
| 18F‐FDG uptake and its clinical relevance in primary gastric lymphoma JH Yi, SJ Kim, JY Choi, YH Ko, BT Kim, WS Kim Hematological oncology 28 (2), 57-61, 2010 | 61 | 2010 |
| 257O Intercontinental cooperative non-Hodgkin T-cell lymphoma prospective registry study in Asia: ICT study SE Yoon, SJ Kim, DH Yoon, TY Chen, Y Koh, KW Kang, HS Lee, ... Annals of Oncology 31, S1343-S1344, 2020 | 1 | 2020 |
| 边缘区淋巴瘤晚期患者 R-CVP 后利妥昔单抗维持治疗的 Ⅱ 期研究: 一项改善淋巴瘤生存协会 (CISL) 的研究 SY Oh, WS Kim, JS Kim, SJ Kim, DH Yoon, DH Yang, WS Lee, HJ Kim, ... | | |
| A case of multiple myeloma recurred as skin involvement HY Seo, JG Choi, H Sul, SJ Kim, JH Seo, BS Kim, SY Yoon The Korean Journal of Medicine 70 (6), 711-714, 2006 | | 2006 |
| A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: a multicenter study KM Tan, B Chia, JQ Lim, LP Khoo, CL Cheng, L Tan, E Poon, ... Scientific Reports 9 (1), 14961, 2019 | 22 | 2019 |
| A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study SE Yoon, Y Eun, K Huh, CR Chung, IY Yoo, J Cho, D Cho, YH Ko, S Park, ... Annals of Hematology 99, 2095-2104, 2020 | 35 | 2020 |
| A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients SH Lee, JS Kim, J Kim, SJ Kim, WS Kim, S Lee, YH Ko, HY Yoo Haematologica 100 (12), e505, 2015 | 53 | 2015 |
| A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study SJ Kim, YR Do, HS Lee, WS Lee, JH Kong, JY Kwak, HS Eom, JH Moon, ... Blood Research 58 (4), 194, 2023 | | 2023 |
| A multi-center, non-randomized phase 2 study of ofatumumab in combination with ICE-chemotherapy (O-ICE) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) T Tang, C Lim, M Tao, R Quek, M Farid, WS Kim, SJ Kim, SH Jeong, ... Blood 124 (21), 5465, 2014 | 2 | 2014 |
| A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). M Ogura, K Ando, N Niitsu, SJ Kim, K Ohmachi, N Takahashi, T Uchida, ... Journal of Clinical Oncology 30 (15_suppl), 8023-8023, 2012 | 7 | 2012 |
| A Multicenter Phase II Trial of Etoposide, Methylprednisolone, High-Dose Cytarabine, and Oxaliplatin (ESHAOx) for Patients with Refractory/Relapsed Aggressive Non-Hodgkin’s … SJ Sym, HJ Kang, SH Nam, H Kim, SJ Kim, HS Eom, WS Kim, C Suh Blood, The Journal of the American Society of Hematology 110 (11), 3446-3446, 2007 | | 2007 |
| A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma SJ Sym, DH Lee, HJ Kang, SH Nam, HY Kim, SJ Kim, HS Eom, WS Kim, ... Cancer chemotherapy and pharmacology 64, 27-33, 2009 | 10 | 2009 |
| A Multicenter Retrospective Analysis of Clinicopathologic Features of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma JH Yi, L Gyeong-Won, YR Do, HJ Yong, C Suh, YS Choi, SY Lee, ... Blood 132, 2909, 2018 | | 2018 |
| A new prognostic index for extranodal natural killer/T-cell lymphoma: incorporation of serum β-2 microglobulin to PINK S Kang, H Cho, S Kim, K Lee, EH Kang, JS Park, YS Lee, CS Park, H Go, ... Cancer Res Treat 55 (1), 314-324, 2023 | 3 | 2023 |
| A novel prognostic model based on pretreatment serum albumin and ECOG PS for primary CNS lymphoma: an international, multi-center study L Wei, Y Gao, KT Prochazka, R Liu, L Wang, B Liu, Y He, L Bertero, ... Journal of Neuro-Oncology 163 (2), 301-311, 2023 | 4 | 2023 |
| A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas SJ Kim, HJ Kang, JS Kim, HS Eom, J Huh, YH Ko, J Lee, DS Yim, SY Lee, ... Investigational new drugs 31, 1514-1521, 2013 | 13 | 2013 |
| A phase II study of brentuximab vedotin for relapsed or refractory CD30-positive non-Hodgkin lymphomas other than anaplastic large cell lymphoma S Park, SJ Kim, JY Hong, DH Yoon, JS Kim, HJ Kang, HS Eom, MH Lee, ... Blood 130, 4077, 2017 | 4 | 2017 |
| A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin’s lymphoma YW Won, H Lee, HS Eom, JS Kim, C Suh, DH Yoon, JY Hong, HJ Kang, ... Annals of Hematology 99, 255-264, 2020 | 3 | 2020 |
| A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas SJ Kim, DY Shin, JS Kim, DH Yoon, WS Lee, H Lee, YR Do, HJ Kang, ... Annals of oncology 27 (4), 712-718, 2016 | 49 | 2016 |
Won Seog kimSamsung Medical CenterVerified email at skku.edu
